Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body
Launched by CUTERA INC. · Aug 5, 2009
Trial Information
Current as of October 13, 2025
Terminated
Keywords
ClinConnect Summary
The purpose of this study is to evaluate the Cutera radio frequency device for the new indication of reduction in size of localized areas of the body, including, but not limited to, areas on the abdomen, leg, and arm.
At investigator's discretion, each subject will receive up to three treatments and will be scheduled for two follow-up visits after the final treatment. The treated area will be measured and photographed ar each visit for analysis. Subjects will also be weighted at each visit and asked to fill out a survey during follow-up visits.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female or Male
- • Minimum age of 18 years
- • Non-smoking for at least 3 months and willing to refrain from smoking for the duration of the study.
- • Post-menopausal, or on birth control with no plans to become pregnant for the duration of the study (female only)
- • Minimum Body Mass Index of 20
- • Visible fat in the area to be treated Area to be treated to measure at least 20.0mm in vertical fold, as measured with industry standard fat caliper
- • Subject must be able to read, understand and sign the Consent Form
- • Subject must adhere to the follow-up schedule and study instructions
- • Subject must adhere to the same diet and/or exercise routine throughout the study, and agree to maintain the same weight throughout the study (within 6 lbs of initial weight)
- Exclusion Criteria:
- • Significant weight fluctuation (+/-10 lbs) in the past 6 months
- • Taking weight-loss medications/supplements
- • Participation in any other clinical study
- • Cellulite treatment within 3 months of the treatment
- • Surgical or non-surgical treatments to the target area in the last 12 months, e.g., liposuction
- • Prior treatment to the target area within the last 12 months
- • Arteriosclerosis or weakened blood vessels
- • Heart disease
- • Thromboembolic disease
- • Diagnosed or documented immune system disorders
- • Bleeding disorders.
- • Presence of uncontrolled hypertension
- • Taking prescription anticoagulants
- • History of keloid formation
- • Malignant tumors in the target area
- • Diabetes
- • Any disease or condition that could impair wound healing
- • Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles
- • Infection in the target area
- • Implanted electrical device(s)
- • Pregnant or lactating
About Cutera Inc.
Cutera Inc. is a leading medical device company specializing in innovative aesthetic solutions for dermatology and plastic surgery. With a commitment to advancing patient care, Cutera develops and manufactures cutting-edge laser and light-based technologies that enhance skin health and appearance. The company is dedicated to clinical research and trials to ensure the safety and efficacy of its products, providing healthcare professionals with reliable tools to meet the evolving demands of the aesthetic market. Through its focus on quality and innovation, Cutera aims to improve patient outcomes and support practitioners in delivering exceptional results.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Danville, California, United States
Dublin, California, United States
Sacramento, California, United States
Montclair, New Jersey, United States
Nashville, Tennessee, United States
Patients applied
Trial Officials
Brian Biesman, MD
Principal Investigator
Jacqueline Calkin, MD
Principal Investigator
Stephen Ronan, MD
Principal Investigator
Scott Kramer, MD
Principal Investigator
Adele Makow, MD
Principal Investigator
Barry DiBernardo, MD
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials